Rare diseases
Investigational molecules
Locations
Study of drug combination in patients with advanced cancer based on genomic profiling - ProTarget Danish nationwide trial
DenmarkStudy on Colon Cancer Treatment Using Disodium Levofolinate and Drug Combination for Patients with Operable Stage III and High-Risk Stage II Colon Cancer
GermanyStudy Comparing Trastuzumab Deruxtecan with Standard Treatment for Patients with HER2-positive Breast Cancer
BelgiumStudy on the Effectiveness of Inavolisib with Trastuzumab and Pertuzumab for Patients with HER2-Positive, HR-Positive, PIK3CA Mutant Early Breast Cancer
BelgiumStudy on Post-Neoadjuvant Therapy for Early Breast Cancer Using Ipatasertib, Inavolisib, and Atezolizumab for Patients with High-Risk Early Breast Cancer
GermanyStudy on Reducing Treatment for Patients with HER2-Positive Metastatic Breast Cancer Using Trastuzumab and Drug Combination After 2 Years of Controlled Disease
FranceStudy of ribociclib with drug combination in early breast cancer patients to test de‑escalated treatment strategies
ItalyMolecularly Tailored Therapy Versus Standard Care in Patients With Advanced Pancreatic Cancer Using Olaparib, Erlotinib, Crizotinib, Trametinib, Pemigatinib, Selpercatinib, Axitinib, Vismodegib, Pembrolizumab, Larotrectinib, Dabrafenib, Capecitabine, Oxaliplatin, Fluorouracil, Irinotecan, Gemcitabine, Paclitaxel Albumin-Bound, and Calcium Folinate
DenmarkStudy of oral TherO2-01S22 with anti-HER2 therapy in patients with metastatic breast cancer
FranceStudy of Atezolizumab, Pertuzumab, and Trastuzumab for Patients with HER2 Positive Early High-Risk and Locally Advanced Breast Cancer
AustriaStudy on the Effectiveness of Trastuzumab, Pertuzumab, and Docetaxel for Patients with Early HER2-Positive Breast Cancer
FinlandStudy of alpelisib with trastuzumab and pertuzumab as maintenance therapy in adult patients with HER2‑positive advanced breast cancer and PIK3CA mutation
FranceTell us about your condition – we search every trial in Europe and connect you with the right site.
